National Bank of Canada
VIR icon

National Bank of Canada’s Vir Biotechnology VIR Stock Holding History

National Bank of Canada’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48K Buy
+145
New +$1.38K ﹤0.01% 2740

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

National Bank of Canada's VIR Position: Q2 2026 in Review

National Bank of Canada opened a new position in Vir Biotechnology (VIR) in Q2 2026: 145 shares worth $1.48K. The stake represents ﹤0.01% of the portfolio and ranks #2740 among its holdings.

237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • National Bank of Canada held 145 shares of Vir Biotechnology worth $1.48K as of Q2 2026.
  • Vir Biotechnology was a new National Bank of Canada position in Q2 2026.
  • Vir Biotechnology made up ﹤0.01% of National Bank of Canada's portfolio in Q2 2026, its #2740 holding.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on National Bank of Canada's 13F filing for Q2 2026, filed 10 Aug 2026.